Ref ID: 2746
Author:
J. STONE1, S. HOLLAND1, P. WICKERSHAM1, P. DEUTSCH1, G. WINCHELL1, M. HESNEY1, R. MILLER1, A. FREEMAN1, S. DILZER2, K. LASSETER2
Author address:
1Merck Research Laboratories, West Point, PA, 2Clinical Pharmacology Associates, Miami, FL.
Full conference title:
ICAAC 41st
Abstract:
Background: Caspofungin (CancidasTM, MK-0991, L-743,872) is a parenteral antifungal agent that inhibits the synthesis of 1,3 b-D glucan, an essential component of the fungal cell wall.
Methods: The potential for drug interactions between caspofungin and tacrolimus (FK-506) was evaluated in a placebo-controlled, randomized, Phase I study. Part (1) was a 2-period, parallel-panel study in which healthy subjects received tacrolimus (2 doses of 0.1 mg/kg oral capsules administered 12 hours apart, n=12) or placebo (n=5) alone in Period 1 and again on Day 10 of caspofungin 70 mg IV daily in Period 2. In Part (2), parallel panels of healthy subjects received tacrolimus (2 doses of 0.1 mg/kg 12 hours apart, n=8) or placebo (n=8) on Days 1 and 10 of caspofungin 50 mg IV daily.
Results: The geometric mean ratio (90% CI) for caspofungin plasma AUC(0-24hr) under coadministration relative to administration alone was 1.00 (0.96, 1.04) for Part (1) and 1.05 (0.96, 1.15) for Part (2), based on a mixed-model analysis that evaluated pharmacokinetic data obtained on Days 9 and 10 in both the coadministration and the placebo-control panels. The geometric mean ratio (90% CI) for tacrolimus whole blood AUC(0-12hr) in Period 2 (coadministration) relative to Period 1 (administration alone) was 0.80 (0.72, 0.89) for Part (1), based on a combined analysis of morning and evening doses. Reductions of similar magnitude were also seen for tacrolimus CMAX and C12hr. Conclusions: Tacrolimus does not alter the pharmacokinetics of caspofungin. Caspofungin modestly reduces whole blood concentrations of tacrolimus. For patients receiving both therapies, standard monitoring of tacrolimus blood concentrations and appropriate tacrolimus dosage adjustments are recommended.
Abstract Number: NULL
Conference Year: 2001
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
KA Holden, KG Staley, EA Gaillard
2016
S71
n/a
-
v
1 A Adlakha, 2 DAJ Armstrong-James, 1 B Lenhard
2016
T1
n/a
-
v
David González De Olano, Lorena Bernal-Rubio, Pía De-Calzada-Bustingorri, Gonzalo De-Los-Santos-Granados, Carlos Almonacid-Sánchez, Belén De-La-Hoz-Caballer
2020
1448
n/a
-
v
Lise Melscoet, Naji Khayath, Frederic De Blay
2020
1246
n/a
-
v
Adeyinka Odebode, Adedotun Adekunle, Ebenezer Farombi
2020
0079
n/a
-
v
Kseniia Suska, Kateryna Gashynova, Valeriia Dmytrychenko
2020
1630
n/a
-
v
Danylo Oleksandrovych Tovstyk, Victoria Rodinkova, Maryna Yasniuk, Olga Kaminska, Iryna Vovk, Olena Palamarchuk
2020
1218
n/a
-
v
Arti Dhawal Shah, Dhawal Niranjan Shah, Amrita Swati, Swati Milani
2020
0390
n/a
-
v
Pauline Percier-Lehebel
2019
LBOA1708
n/a